Recent Advances in the Diagnosis and Treatment of Relapsed and Refractory Lymphoid Malignancies
A Special Issue of Hematology Reports (ISSN 2038-8330).
Deadline for manuscript submissions: 30 October 2026 | Viewed by 285
Editors
Interests: lymphoma; epidemiology; bone marrow transplantation; chimeric antigen T-cell therapy
Special Issue Information
Dear Colleagues,
Over the past decade, there have been numerous advances in the diagnosis and treatment of lymphoid malignancies. These include developments in disease classification, risk stratification, and novel therapies. Cytogenetic and molecular tests are being used at the time of diagnosis to better classify lymphoid neoplasms and plan their treatments. Testing for measurable residual disease is being incorporated into new treatment protocols to assess response to therapy and risk of relapse. Novel therapies are being used to help patients live longer, including chimeric antigen receptor T-cell therapy, targeted therapies, and bispecific T-cell engagers.
In this Special Issue, we invite authors to submit original research and reviews regarding the diagnosis and treatment of relapsed refractory lymphoid malignancies, including B- and T-cell leukemias and lymphomas. We welcome studies that report the results of new treatments in real-world settings, studies that test novel treatment combinations, and those that integrate new diagnostic and treatment approaches.
Dr. John L. Vaughn
Dr. Marc J. Braunstein
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hematology Reports is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- T-cell lymphoma
- B-cell lymphoma
- bispecific antibodies
- adoptive immunotherapy
- residual neoplasm
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
